Inventurus Knowledge Solutions Limited has informed the Exchange about Transcript
IKS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
IKS Health reported Q1 FY26 results with revenue of ~Rs. 740 crores, up 16% YoY (13% constant currency), and EBITDA margin expanding 90bps QoQ to 32% (36% YoY growth). Profit after tax grew nearly 59% YoY to Rs. 151 crores, with EPS at Rs. 9 (up 58% YoY). Headcount fell 7% YoY to 12,368 even as revenue grew, reflecting the shift from human-led to tech-led delivery. AQuity integration margin expansion is running ahead of plan (about two-thirds done toward the early-to-mid 30s target), while customer wins include Sky Lakes Health System, Mission Community (second end-to-end acute RCM deal), Bicycle Health, and OrthoNY expansion. Long-duration outcome-based deals like Palomar and Western Washington are progressing ahead of plan, with Palomar expected to be fully implemented by end of fiscal Q2.
Strong quarter reinforces margin expansion trajectory toward the early-to-mid 30s EBITDA target and supports continued PAT outperformance as interest costs decline on debt paydown (net debt at Rs. 448 crores). Likely positive for stock sentiment given revenue beat, margin expansion, and visible strategic progress on AI-native platform, AQuity synergies, and long-tenor outcome deals.